Tag Archives: Cell

FDA Approves Rybrevant (amivantamab-vmjw) as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

FDA Approves Rybrevant (amivantamab-vmjw) as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations May 21, 2021 (HORSHAM, P.A.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has granted the accelerated approval of Rybrevant (amivantamab-vmjw) for the… Read More »

These Sisters With Sickle Cell Had Devastating, and Preventable, Strokes

Kyra, left, and Kami Crawford, of San Antonio, are both living with sickle cell, a common complication of which is stroke. These Sisters With Sickle Cell Had Devastating, and Preventable, Strokes Kyra and Kami never got a simple test that could have protected them. Their story exemplifies the failure to care for people with the… Read More »

Chiesi Global Rare Diseases Announces FDA Approval of Ferriprox (deferiprone) for Treatment of Transfusional Iron Overload due to Sickle Cell Disease

May 1, 2021 Approval is based on demonstrated reduction in liver iron concentration Expanded indications for patients with sickle cell disease or other anemias, as well as thalassemia – BOSTON, May 1, 2021 /PRNewswire/ — Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), announced today… Read More »

FDA Approves Tabrecta (capmatinib) for Metastatic Non-Small Cell Lung Cancer with METex14

FDA Approves Tabrecta (capmatinib) for Metastatic Non-Small Cell Lung Cancer with METex14 Print this page EAST HANOVER, N.J., May 6, 2020 /PRNewswire/ — Novartis announced today that the US Food and Drug Administration (FDA) approved Tabrecta™ (capmatinib, formerly INC280), an oral MET inhibitor for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that… Read More »

‘Executioner cell’ find may help to treat the causes of blindness

Researchers at Trinity College Dublin have identified a so-called “executioner cell” that may hold the key to eventually finding a treatment to slow retinal degeneration that causes blindness in millions of people each year. A multi-disciplinary team involving experts from TCD believe they have pinpointed a potential new therapeutic target for treating retinal degeneration. It… Read More »